Aakaar Medical Technologies IPO Open Now

Mumbai, India, June 20, 2025: Aakaar Medical Technologies Ltd has launched its Initial Public Offering (IPO) today, aiming to raise ₹27 crore from the public markets. The subscription window for the IPO is open from June 20, 2025, and will close on June 24, 2025.

IPO Structure and Listing:

The ₹27 crore issue is entirely a fresh issue, meaning all 37.5 lakh equity shares being offered will infuse capital directly into the company for its growth and operations. There is no Offer for Sale (OFS) component, which would involve existing shareholders selling their shares.

The shares are set to be listed on the NSE SME platform, Emerge, with a tentative listing date of June 27, 2025.

Aakaar Medical Technologies IPO Details at a Glance:

• IPO Price Band: ₹68 to ₹72 per equity share.
• Face Value: ₹10 per equity share.
• Minimum Lot Size for Application: 1,600 shares.
• Minimum Investment for Retail Investors: ₹1,08,800 (at the lower end of the price band).
• Tentative Allotment Finalisation Date: Wednesday, June 25, 2025.
• Initiation of Refunds: Thursday, June 26, 2025.
• Credit of Shares to Demat Account: Thursday, June 26, 2025.

Company Overview:

Founded in 2013 and headquartered in Mumbai, Aakaar Medical Technologies specialises in the manufacturing of medical devices and dermatological products. Its product portfolio includes ointments and equipment primarily used for aesthetic and dermatological treatments. The company operates under a B2B (business-to-business) model, supplying products to dermatologists, plastic surgeons, aesthetic physicians, and clinic chains across India.

Aakaar Medical Technologies offers a mix of domestically manufactured products under its own brands and also distributes imported medical aesthetic devices from countries like Korea, Spain, Italy, and Austria. As of March 31, 2025, the company had 154 Stock Keeping Units (SKUs), with 60 being its own brands and 94 imported brands.

Financial Performance:

Aakaar Medical Technologies has demonstrated consistent financial growth:

The company’s revenue increased by approximately 33%, and profit after tax rose by about 110% between FY24 and FY25.

Objects of the Issue:

The primary objectives for utilising the IPO proceeds are:

• Funding working capital requirements: Approximately ₹20.35 crore will be used to meet the company’s day-to-day operational needs.
• General corporate purposes: The remaining funds will be allocated for general operational and strategic needs.

Promoter Holding:

• Pre-Issue Promoter Holding: 91.11%
• Post-Issue Promoter Holding: Will decrease after the IPO due to the fresh issue of shares.

Investor Categories:

The IPO has specific reservations for different investor categories:

• Qualified Institutional Buyers (QIBs): Up to 50% of the Net Issue (including 28.44% for Anchor Investors, who bid on June 19, 2025).
• Non-Institutional Investors (NIIs): At least 15% of the Net Issue.
• Retail Individual Investors (RIIs): At least 35% of the Net Issue.

Lead Manager and Registrar:

• Book Running Lead Manager: Indorient Financial Services Ltd.
• Registrar to the Issue: Bigshare Services Pvt Ltd.

Investors interested in the Aakaar Medical Technologies IPO can apply online through their bank’s ASBA (Applications Supported by Blocked Amount) facility via net banking or through their stockbroker.

Looking Ahead

The IPO offers investors the opportunity to participate in a growing medical devices company with improving financials and a focused B2B business model. The absence of an OFS signals promoter confidence, and proceeds will strengthen working capital. However, the relatively high minimum investment (₹1.08 lakh) may limit retail participation. Investors should monitor subscription trends and compare valuations with those of their peers in the SME segment before making a decision.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations